62 results on '"M. CAMPAYO"'
Search Results
2. 1278P ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
- Author
-
Nadal, E., Fernandez, C. Alvarez, Arasanz, H., Muñoz, S. Peralta, Quintela, M. Lázaro, Teixido, C., Calvo de Juan, V., Alvarez, R.M., Espinar, J. Baena, Valdivia-Bautista, J., Arriola, E., Lastra, R., Caro, R. Bernabe, Camacho, C., Cordellat, A. Blasco, Sureda, B. Massuti, Guillaumes, M. Campayo, Dols, M. Cobo, Manrique, T. Garcia, and Marquez, G.J.
- Published
- 2023
- Full Text
- View/download PDF
3. MA08.09 Results of Trimodality Therapy for Patients with cN2 Lung Cancer Diagnosed by Video-Assisted Mediastinoscopic Lymphadenectomy (VAMLA)
- Author
-
Mireia Serra-Mitjans, José Belda-Sanchis, Ramón Rami-Porta, F. Perez Ochoa, S. Catot, Carme Obiols, Sergi Call, M. Campayo, and M. Nuñez
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Oncology ,business.industry ,medicine.medical_treatment ,medicine ,Video assisted ,Lymphadenectomy ,Radiology ,Lung cancer ,medicine.disease ,business - Published
- 2019
- Full Text
- View/download PDF
4. Experimental validation of a MCNP-based model to predict portal dose images from MLC beams
- Author
-
Belén Juste, Gumersindo Verdú, Rafael Miró, Sergio Diez, J. M. Campayo, Spain Valencia, and Daniel Morera
- Subjects
business.industry ,Computer science ,Monte Carlo method ,Conformal radiation therapy ,Collimator ,General Medicine ,Experimental validation ,Signal ,Linear particle accelerator ,law.invention ,Root mean square ,law ,Calibration ,Nuclear medicine ,business ,Biomedical engineering - Abstract
This work presents a technique to perform an electronic portal imaging device (EPID) signal planar calibration into dose terms using Monte Carlo simulations. To that, a complete Monte Carlo (MC) simulation of a radiotherapy treatment linear accelerator including a multi-leaf collimator system (MLC) and an EPID has been developed. Several solid water blocks were used to obtain calibration measurements and simulations with a large dose range in order to study the relation between the squared EPID response and the MC calculated dose. The calibrated EPID has also been used as a dosimetric tool to validate the MC MLC Linac model. Simulation and measurement comparisons are below 5% root mean square of percentage dose difference. This technique could potentially provide a more accurate verification of dose delivery to heterogeneous anatomical regions in patients receiving complex multi-field conformal radiation therapy treatments.
- Published
- 2014
- Full Text
- View/download PDF
5. Determination of the primary X-ray spectrum using a PMMA wedge, a flat panel and the Monte Carlo method
- Author
-
Sergio Gallardo, Belén Juste, Andrea Querol, Fausto Pozuelo, Gumersindo Verdú, José Ródenas, Juan M. Campayo, and Sergio Díez
- Subjects
Physics ,Matrix (mathematics) ,Optics ,business.industry ,Electromagnetic shielding ,Monte Carlo method ,Singular value decomposition ,General Medicine ,Radiation protection ,business ,Wedge (geometry) ,Beam (structure) ,Flat panel detector - Abstract
An accurate knowledge of the photon spectra emitted by X-ray tubes in radiodiagnostic is essential to better estimate the imparted dose to patients and to improve the quality image obtained with these devices. However, it is difficult to measure the energy spectrum of these tubes due to the pile up effect produced by the high fluence of X-ray beams. In this work, it is proposed the use of a flat panel detector together with a PMMA wedge to obtain a dose distribution for different high voltages. The relation between the dose curve recorded by the flat panel and the primary beam X-ray spectrum is defined by a Response matrix. The MCNP5 code based on the Monte Carlo method has been used to simulate the actual experimental acquisition including the X-ray tube, the PMMA wedge and a flat panel. A Response matrix has been obtained by means of different monochromatic beams. Knowing the dose distribution for a given conditions and the Response matrix, the primary spectrum can be obtained. The Modified Truncated Singular Value Decomposition (MTSVD) method has been applied to unfold primary spectra using Matlab © algorithms. Unfolded spectra are compared with theoretical X-ray spectra obtained from IPEM 78 catalogue report. Results show that the hybrid technique -experimental-Monte Carlo method- could represent a valid tool in order to complement the Quality Control of X-ray tubes in the radiodiagnostic energy range.
- Published
- 2014
- Full Text
- View/download PDF
6. Quality Assurance Applied to Digital Radiographic Equipment by Developed Software for Phantom Images
- Author
-
B. Marín, F. Rodenas, J. M. Campayo, Gumersindo Verdú, and P. Mayo
- Subjects
Nuclear and High Energy Physics ,medicine.medical_specialty ,Radiographic imaging ,Computer science ,Image quality ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,Equipment ,INGENIERIA NUCLEAR ,Software testing ,Imaging phantom ,Task (project management) ,Radiographic phantom ,Automated image analysis ,Digital image ,Software ,Image quality assessment ,medicine ,Medical physics ,Digital equipment ,Good practice ,Operating condition ,business.industry ,Radiographic equipment ,Quality control ,Condensed Matter Physics ,Quality assurance ,Phantom images ,Nuclear Energy and Engineering ,Good practices ,Radiology ,MATEMATICA APLICADA ,business - Abstract
[EN] The assessment and control of image quality is a fundamental task associated with good practice to guarantee a suitable diagnosis by the radiologist. The need for image quality assessments in radiography is well established, and the use of test phantoms is a common method for this purpose. In this work we present a developed tool that consists of a specific phantom (named RACON) that is used for acceptance and constancy test in order to analyze the image obtained by digital radiographic equipment, software (named SoftRACON) for automated image analysis with digital processing techniques, and a database to store test phantom images and the scoring results. The main objective is to characterize the constancy of the radiographic imaging chain and guarantee acceptable image quality, related to well-functioning of the radiographic equipment. Therefore, the application presented in this work is sensitive enough to the operating conditions of the radiographic digital equipment and allows the assessment of the imaging system quality and, consequently, increases the objectivity (accuracy) in the evaluation of the image.
- Published
- 2011
- Full Text
- View/download PDF
7. Neutron distribution and induced activity inside a Linac treatment room
- Author
-
Gumersindo Verdú, Rafael Miró, Belén Juste, J. M. Campayo, and Sergio Diez
- Subjects
Physics ,Neutrons ,Medical staff ,Physics::Medical Physics ,Treatment room ,Induced radioactivity ,Particle accelerator ,Dose-Response Relationship, Radiation ,Photon energy ,Models, Theoretical ,Rotation ,Linear particle accelerator ,law.invention ,Nuclear physics ,law ,Physics::Accelerator Physics ,Humans ,Neutron ,Particle Accelerators ,Nuclear Experiment ,Monte Carlo Method - Abstract
Induced radioactivity and photoneutron contamination inside a radiation therapy bunker of a medical linear accelerator (Linac) is investigated in this work. The Linac studied is an Elekta Precise electron accelerator which maximum treatment photon energy is 15 MeV. This energy exceeds the photonuclear reaction threshold (around 7 MeV for high atomic number metals). The Monte Carlo code MCNP6 has been used for quantifying the neutron contamination inside the treatment room for different gantry rotation configuration. Walls activation processes have also been simulated. The approach described in this paper is useful to prevent the overexposure of patients and medical staff.
- Published
- 2016
8. MCNP simulation of a Theratron 780 radiotherapy unit
- Author
-
Gumersindo Verdú, J. M. Campayo, J. Soler, Rafael Miró, Sergio Gallardo, and Sergio Diez
- Subjects
Materials science ,Radiotherapy unit ,law.invention ,Radiation Protection ,Optics ,law ,Field size ,Computer Simulation ,Radiology, Nuclear Medicine and imaging ,Cobalt Radioisotopes ,Radiometry ,Models, Statistical ,Radiation ,Radiotherapy ,Radiological and Ultrasound Technology ,business.industry ,Public Health, Environmental and Occupational Health ,Radiotherapy Dosage ,Collimator ,General Medicine ,Equipment Failure Analysis ,Monte carlo code ,Nuclear medicine ,business ,Monte Carlo Method ,Algorithms ,Beam (structure) - Abstract
A Theratron 780 (MDS Nordion) "Co radiotherapy unit has been simulated with the Monte Carlo code MCNP. The unit has been realistically modelled: the cylindrical source capsule and its housing, the rectangular collimator system, both the primary and secondary jaws and the air gaps between the components. Different collimator openings, ranging from 5 x 5 cm 2 to 20 x 20 cm 2 (narrow and broad beams) at a source-surface distance equal to 80 cm have been used during the study. In the present work, we have calculated spectra as a function of field size. A study of the variation of the electron contamination of the 6 0 Co beam has also been performed.
- Published
- 2005
- Full Text
- View/download PDF
9. A comparative study of computer assisted assessment of image quality index for mammographic phantom images
- Author
-
P. Mayo, Gumersindo Verdú, F. Rodenas, J. I. Villaescusa, and J. M. Campayo
- Subjects
Quality Assurance, Health Care ,Computer science ,Image quality ,Noise reduction ,Sensitivity and Specificity ,Imaging phantom ,Digital image ,Digital image processing ,Preprocessor ,Radiology, Nuclear Medicine and imaging ,Computer vision ,Image resolution ,Radiation ,Radiological and Ultrasound Technology ,Phantoms, Imaging ,business.industry ,Public Health, Environmental and Occupational Health ,Reproducibility of Results ,General Medicine ,Radiographic Image Enhancement ,Line (geometry) ,Radiographic Image Interpretation, Computer-Assisted ,Artificial intelligence ,business ,Algorithms ,Mammography - Abstract
Mammographic phantom images are usually used to study the quality of images obtained by dedicated mammographic equipment. The digital image treatment techniques allow us to carry out an automatic analysis of the phantom image. In this work, some techniques of digital image processing are applied to compute a specific image quality index (IQI) for a mammographic phantom, namely CIRS model 11A version SP01. The algorithm designed analyses the phantom image by means of automatic detection of the number of microcalcifications, and the image resolution as the number of line pairs per millimetre. Then, the IQI is calculated from a scoring system. The manner in which the functioning conditions (kV and mAs) of the mammographic equipment and the preprocessing denoising method of the digital image affect the results for the IQI are also studied.
- Published
- 2005
- Full Text
- View/download PDF
10. Neutron activation processes simulation in an Elekta medical linear accelerator head
- Author
-
Rafael Miró, Sergio Diez, Gumersindo Verdú, J. M. Campayo, and Belén Juste
- Subjects
Neutrons ,Physics ,Photons ,Photon ,Monte Carlo method ,Equipment Design ,Models, Theoretical ,Linear particle accelerator ,Nuclear physics ,Head (vessel) ,Neutron ,Particle Accelerators ,Photon beam ,Monte carlo estimation ,Monte Carlo Method ,Neutron activation - Abstract
Monte Carlo estimation of the giant-dipole-resonance (GRN) photoneutrons inside the Elekta Precise LINAC head (emitting a 15 MV photon beam) were performed using the MCNP6 (general-purpose Monte Carlo N-Particle code, version 6). Each component of LINAC head geometry and materials were modelled in detail using the given manufacturer information. Primary photons generate photoneutrons and its transport across the treatment head was simulated, including the (n, γ) reactions which undergo activation products. The MCNP6 was used to develop a method for quantifying the activation of accelerator components. The approach described in this paper is useful in quantifying the origin and the amount of nuclear activation.
- Published
- 2014
- Full Text
- View/download PDF
11. Quality assurance applied to mammographic equipments using phantoms and software for its evaluation
- Author
-
P. Mayo, J. M. Campayo, F. Rodenas, and Gumersido Verdú
- Subjects
Physics ,Nuclear and High Energy Physics ,medicine.medical_specialty ,business.industry ,Radiographic equipment ,Image quality ,media_common.quotation_subject ,Imaging phantom ,Digital image ,Software ,Digital image processing ,medicine ,Medical physics ,Computer vision ,Quality (business) ,Artificial intelligence ,business ,Instrumentation ,Quality assurance ,media_common - Abstract
The image quality assessment in radiographic equipments is a very important item for a complete quality control of the radiographic image chain. The periodic evaluation of the radiographic image quality must guarantee the constancy of this quality to carry out a suitable diagnosis. Mammographic phantom images are usually used to study the quality of images obtained by determined mammographic equipment. The digital image treatment techniques allow to carry out an automatic analysis of the phantom image. In this work we apply some techniques of digital image processing to analyze in an automatic way the image quality of mammographic phantoms, namely CIRS SP01 and RACON for different varying conditions of the mammographic equipment. The CIRS SP01 phantom is usually used in analogic mammographic equipments and the RACON phantom has been specifically developed by authors to be applied to acceptance and constancy tests of the image quality in digital radiographic equipments following recommendations of international associations. The purpose of this work consists in analyzing the image quality for both phantoms by means of an automatic software utility. This analysis allows us to study the functioning of the image chain of the mammographic system in an objective way, so an abnormal functioning of the radiographic equipment might be detected.
- Published
- 2010
- Full Text
- View/download PDF
12. A new methodology to determinate linac photon spectra using the EPID signal
- Author
-
Rafael Miró, Ana Jambrina, J. M. Campayo, Sergio Diez, Belén Juste, and Gumersindo Verdú
- Subjects
Physics ,Radiation ,Photon ,business.industry ,Monte Carlo method ,Physics::Medical Physics ,INGENIERIA NUCLEAR ,Signal ,Linear particle accelerator ,Matrix (mathematics) ,Linac photon spectra EPID ,Optics ,Spectrum reconstruction ,Biomedical applications of radiation ,Singular value decomposition ,Elekta radiotherapy unit ,business ,Monte Carlo Method ,Energy (signal processing) ,Beam (structure) ,MCNP5 - Abstract
A precise estimation of the photon spectra emitted by radiation therapy Linacs is especially important to accurately estimate the dose received by patients in order to improve treatment plannings. Moreover the knowledge of the spectra is useful to perform routinely Quality Control procedures of these equipments. In this work we propose the use of the Elekta Linac EPID (Electronic Portal Imaging Device) to obtain the fluence spectrum emitted by this unit. To that, several images using different thicknesses of solid water slabs have been taken with the EPID, setting 100 UM, a 10 cm×10 cm field size and a 6 MeV energy beam. The relation between the signal response recorded by the EPID with several solid water slabs and the primary photon spectrum emitted is calculated by means of a Response matrix, which has been performed via Monte Carlo simulations. To that, the MCNP5 code has been used to simulate the EPID signal response obtained after irradiation with consecutive monoenergetic beams for different slabs. Each row of the Response Matrix represents the Monte Carlo EPID signal registered using a specific energy bin. Since this matrix is ill conditioned we have applied the Truncated Singular Value Decomposition algorithms to unfold the spectra. Results have been compared with theoretical spectrum, showing that the mixed methodology (experimental-Monte Carlo simulation) can offer an accurate way to determinate the photon spectrum in radiation therapy.
- Published
- 2014
- Full Text
- View/download PDF
13. Comparison between transmission and scattering spectrum reconstruction methods based on EPID images
- Author
-
A. Jambrina, A. Santos, J. M. Campayo, Sergio Diez, R. Miro, B. Juste, and Gumersindo Verdú
- Subjects
Physics ,Photons ,Silicon ,Photon ,Scattering ,business.industry ,Monte Carlo method ,Monte Carlo method for photon transport ,Radiation ,System of linear equations ,Linear particle accelerator ,Optics ,Robustness (computer science) ,Image Processing, Computer-Assisted ,Scattering, Radiation ,Radiotherapy, Intensity-Modulated ,Particle Accelerators ,business ,Monte Carlo Method ,Algorithms - Abstract
Numerous improved physics-based methods for Linac photon spectra reconstruction have been published; some of them are based on transmission data analysis and others on scattering data. In this work, the two spectrum unfolding approaches are compared in order to experimentally validate its robustness and to determine which is the optimal methodology for application on a clinical quality assurance routine. Both studied methods are based on EPID images generated when the incident photon beam impinges onto plastic blocks. The distribution of transmitted/scatter radiation produced by this object centered at the beam field size was measured. Measurements were performed using a 6 MeV photon beam produced by the linear accelerator. The same radiation distribution conditions were also simulated with Monte Carlo code for a series of monoenergetic identical geometry photon beams for both cases. Two systems of linear equations were generated to combine the polyenergetic EPID measurements with the monoenergetic simulation results. Regularization techniques were applied to solve the systems for obtaining the incident photon spectrum. We present a comparison between the well-known photon Spectral Reconstruction based on Transmission Data (Trans-based) technology and the Spectral Reconstruction based on Scattering Data (Scatt-based), which we both developed using EPID images. It is shown that Trans-based reconstruction results display much better agreement with photon spectrum theoretical predictions.
- Published
- 2013
14. Nuclear MCNP simulation of the photoneutron dose contribution in linac radiotherapy treatments with multileaf collimation systems
- Author
-
Sergio Diez, Rafael Miró, Belén Juste, Gumersindo Verdú, and J. M. Campayo
- Subjects
Physics ,business.industry ,medicine.medical_treatment ,Monte Carlo method ,Collimator ,Photon energy ,Linear particle accelerator ,Collimated light ,law.invention ,Radiation therapy ,Optics ,law ,medicine ,Dosimetry ,business ,Nuclear medicine ,Beam (structure) - Abstract
External Bremsstrahlung photon beams produced by medical linac accelerators (Linac) are the most commonly used radiation therapy treatments. The case of treatments which include photon energy beam exceeding 10 MeV produce an undesired dose received by patients due to photoneutron production in the accelerator head. Currently, sophisticated techniques such as multileaf collimators are used for a better definition of the target volume irradiation. In these cases it is important to evaluate the photoneutron dose produced by the excitation of the high atomic number materials (mainly tungsten) constituting the collimator leaves in order to optimize the radiation therapy treatment. A Monte Carlo simulation has been developped to calculate the photoneutron dose arising from an Elekta Precise unit head using a 15 MeV photon beam. The simulation has been performed using the MCNP5 code. Results are presented for the facility at Hospital Universitari Clinic de Valencia setting a square 10 cm × 10 cm collimator configuration.
- Published
- 2011
- Full Text
- View/download PDF
15. Linac photon spectra reconstruction using a depth dose gradient TSVD methodology based on Monte Carlo simulation
- Author
-
Rafael Miró, Sergio Diez, J. M. Campayo, Gumersindo Verdú, and Belén Juste
- Subjects
Physics ,Optics ,Photon ,Spectral power distribution ,business.industry ,Physics::Medical Physics ,Monte Carlo method ,Calibration ,Dosimetry ,Monte Carlo method for photon transport ,business ,Spectral line ,Imaging phantom - Abstract
Megavoltage photon beams are widely used for radiation therapy treatments, and the precise knowledge of their spectral distribution is important for accurate dose calculations. There are several methods that can offer reasonable estimations of linac photon spectra based on measured depth dose distributions in a water tank. However, this reconstruction problem is an inverse radiation transport function which is poorly conditioned and its solution may become unstable due to small perturbations in the input data. We present here a novel and more stable method which can be used for photon spectral reconstruction without any prior knowledge of spectral distribution. This technique involves measuring the depth dose curve in a water phantom and applying an unfolding method using Monte Carlo simulated depth dose gradient curves for consecutives mono-energetic beams. It is shown that the relative errors in dose calculations, using the spectra reconstructed via this method, are significantly smaller than those obtained via the traditional reconstruction algorithms. These results suggest that this gradient algorithm could be useful in linac photon spectra routines calibration.
- Published
- 2011
- Full Text
- View/download PDF
16. 6 and 15 MeV photon spectra reconstruction using an unfolding depth dose gradient methodology
- Author
-
J. M. Campayo, Sergio Diez, Rafael Miró, Belén Juste, and Gumersindo Verdú
- Subjects
Physics ,Models, Statistical ,Spectral power distribution ,business.industry ,Radiotherapy Planning, Computer-Assisted ,MECANICA DE FLUIDOS ,Monte Carlo method ,Physics::Medical Physics ,Dose profile ,Dose-Response Relationship, Radiation ,Radiotherapy Dosage ,Function (mathematics) ,Photon spectra ,INGENIERIA NUCLEAR ,Models, Biological ,Imaging phantom ,Optics ,Computer Simulation ,Radiotherapy, Conformal ,Cube ,Radiometry ,business ,Radiation treatment planning ,Algorithms - Abstract
[EN] An accurate knowledge of the spectral distribution emission is essential for precise dose calculations in radiotherapy treatment planning. Reconstruction of photon spectra emitted by medical accelerators from measured depth dose distributions in a water cube is an important tool for commissioning a Monte Carlo treatment planning system. However, the reconstruction problem is an inverse radiation transport function which is poorly conditioned and its solution may become unstable due to small perturbations in the input data. In this paper we present a more stable spectral reconstruction method which can be used to provide an independent confirmation of source models for a given machine without any prior knowledge of the spectral distribution. This technique involves measuring the depth dose curve in a water phantom and applying an unfolding method using Monte Carlo simulated depth dose gradient curves for consecutives mono-energetic beams. We illustrate this theory to calculate a 6 and a 15 MeV photon beam emitted from an Elekta Precise radiotherapy unit using the gradient of depth dose curves in a cube-shaped water tank.
- Published
- 2011
- Full Text
- View/download PDF
17. Bremsstrahlung spectrum reconstruction from gradient depth dose curves obtained in a water phantom
- Author
-
Belén Juste, Gumersindo Verdú, Rafael Miró, J. M. Campayo, and Sergio Diez
- Subjects
Nuclear and High Energy Physics ,Spectral power distribution ,020209 energy ,Physics::Medical Physics ,02 engineering and technology ,INGENIERIA NUCLEAR ,Noise (electronics) ,Imaging phantom ,Tikhonov regularization ,Superposition principle ,Optics ,0203 mechanical engineering ,Spectrum reconstruction ,0202 electrical engineering, electronic engineering, information engineering ,Dosimetry ,Monte Carlo simulation ,Physics ,business.industry ,Bremsstrahlung ,Inverse problem ,Condensed Matter Physics ,Computational physics ,020303 mechanical engineering & transports ,Nuclear Energy and Engineering ,business ,MCNP5 - Abstract
[EN] Megavoltage sources are commonly used in radiotherapy treatments, and the determination of the spectral distribution of a photon beam is extremely important for exact dosimetry and for the calculation of therapeutic dose distributions. Since direct measurements of the spectrum are very difficult, we present a technique to accurately calculate the bremsstrahlung spectra based on a numerical reconstruction upon central-axis depth dose data measured in a water tank using inverse methods. The basic idea of this technique is that the measured depth dose curve can be expressed as a weighted superposition of monoenergetic depth dose curves. While traditional approaches directly use the measured depth dose data, we show the improvement of using the gradient of these data for reconstruction. The inverse problem in terms of gradients is shown to be markedly less illconditioned than the usual inverse problem. In each case, a Tikhonov regularization is introduced to minimize the effects of noise due to measurement and computation. We illustrate this theory to calculate a 6-MeV photon beam from an Elekta Precise radiotherapy unit utilizing the gradient of depth dose measurements in a water tank.
- Published
- 2011
18. Electron influence on the reconstruction of a linac 6 MeV photon spectra by unfolding methods
- Author
-
Sergio Diez, J. M. Campayo, Belén Juste, Rafael Miró, and Gumersindo Verdú
- Subjects
Physics ,Photons ,Photon ,Spectral power distribution ,Physics::Medical Physics ,Monte Carlo method ,Dose profile ,Electrons ,Equipment Design ,Electron ,Models, Theoretical ,Radiation Dosage ,Imaging phantom ,Linear particle accelerator ,Computational physics ,Equipment Failure Analysis ,Computer-Aided Design ,Scattering, Radiation ,Dosimetry ,Computer Simulation ,Particle Accelerators ,Atomic physics - Abstract
Megavoltage photon sources are normally used for radiotherapy treatments. For these equipments an accurate knowledge of their spectral distribution is essential for accurate dose calculations planning. There are several ways to determine the spectrum of a clinical photon beam: direct measurement, electron source modelling or reconstruction from experimental measures. In this paper we focus on the latter type of spectral reconstruction methods which can be used to provide an independent confirmation of source models for a given machine without any prior knowledge of the spectral distribution. This technique involves measuring the depth dose curve in a water phantom and applying an unfolding method using Monte Carlo simulated depth dose curves for consecutives mono-energetic beams. We illustrate this theory to calculate a 6 MeV photon beam from an Elekta Precise radiotherapy unit using the gradient of depth dose measurements in a cube-shaped water tank.
- Published
- 2010
- Full Text
- View/download PDF
19. Comparison of experimental 3D dose curves in a heterogeneous phantom with results obtained by MCNP5 simulation and those extracted from a commercial treatment planning system
- Author
-
Gumersindo Verdú, Sergio Diez, Belén Juste, Rafael Miró, and J. M. Campayo
- Subjects
Physics ,Radiation ,Photon ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Monte Carlo method ,Radiotherapy Dosage ,Dose distribution ,Models, Biological ,Imaging phantom ,Software ,Radiometry ,Computer Simulation ,Photon beam ,Radiotherapy, Conformal ,Biological system ,Nuclear medicine ,business ,Radiation treatment planning ,Monte Carlo Method ,Algorithms - Abstract
Commercial planning systems used in radiotherapy treatments use determinist correlations to evaluate dose distribution around regions of interest. Estimated dose with this type of planners can be problematic, especially when analyzing heterogeneous zones. The present work is focused in quantifying the dose distribution in a heterogeneous medium irradiated by a 6 MeV photon beam emitted by an Elekta Precise Radiotherapy Unit head. Dose mapping inside the heterogeneous water phantom has been simulated with the photon and electron transport with Monte Carlo computer code MCNP5 and also, using a commercial treatment planning software in the same irradiation conditions. The calculated results were compared with experimental relative dose curves. This comparison shows that inside the heterogeneity region, the commercial algorithms are not able to predict the variation of dose in the heterogeneous zones with the same precision as MCNP5.
- Published
- 2009
20. Monte Carlo simulation of the iView GT portal imager dosimetry
- Author
-
Gumersindo Verdú, Rafael Miró, Belén Juste, Sergio Diez, and J. M. Campayo
- Subjects
Physics ,Attenuator (electronics) ,Radiation ,Models, Statistical ,Pixel ,business.industry ,Monte Carlo method ,Reproducibility of Results ,Equipment Design ,Photon energy ,Sensitivity and Specificity ,Imaging phantom ,Equipment Failure Analysis ,Optics ,Radiology Information Systems ,Region of interest ,Ionization chamber ,Dosimetry ,Computer-Aided Design ,Computer Simulation ,Nuclear medicine ,business ,Radiometry ,Monte Carlo Method - Abstract
This work is mainly focused on developing a methodology to obtain portal dosimetry with an amorphous silicon electronic portal image device (EPID) by means of Monte Carlo simulations and experimental measures. According to this, pixel intensity values of portal images have been compared with dose measured from an ionization chamber and dose obtained from Monte Carlo simulations. To that, several images were acquired with the Elekta iView GT EPID using an attenuator phantom slab (10 cm thickness of solid water) and a 6 MV photon energy beam with different monitor units. The average pixel value in a region of interest (ROI) centered at the beam selecting each image was extracted and compared to dose measures performed with the ionization chamber. These parameters were found to be linearly correlated with the number of monitor units (MU). Since, MCNP5 simulations allow calculating the deposited dose in the ROI within the phosphor layer of the EPID model, we can compare the portal dose with the simulated transit dose in order to perform a treatment control.
- Published
- 2009
21. Analysis of digital image quality indexes for CIRS SP01 and CDMAM 3.4 mammographic phantoms
- Author
-
J. M. Campayo, J. I. Villaescusa, P. Mayo, G. Verdu, and F. Rodenas
- Subjects
Quality Control ,Standard test image ,Quality Assurance, Health Care ,Image quality ,business.industry ,Computer science ,Phantoms, Imaging ,Radiography ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,Imaging phantom ,Radiographic Image Enhancement ,Digital image ,Quality (physics) ,Spain ,Digital image processing ,Radiographic Image Interpretation, Computer-Assisted ,Computer vision ,Artificial intelligence ,business ,Mammography - Abstract
Mammographic phantom images are usually used to study the quality of images obtained by determined mammographic equipment. The digital image treatment techniques allow carrying out an automatic analysis of the phantom image. Nowadays, the digital radiographic equipments are replacing the traditional film-screen equipments and it is necessary to update the parameters to guarantee the quality of the process. In this work we apply some techniques of digital image processing to compute a specific image quality indexes for mammographic phantoms, namely CIRS SP01 and CDMAM 3.4. to study the evolution of this parameter with different varying conditions of the mammographic equipment. The indexes are calculated from a scoring system based on a designed algorithm which analyses the phantom image by means of an automatic detection of the test objects in each phantom.
- Published
- 2009
22. Digital image quality indexes for CIRS SP01 and CDMAM 3.4 mammographic phantoms
- Author
-
P. Mayo, J. M. Campayo, F. Rodenas, and Gumersindo Verdú
- Subjects
Digital image ,Quality (physics) ,Scoring system ,Image quality ,Computer science ,business.industry ,Digital image processing ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,Image processing ,Computer vision ,Artificial intelligence ,business ,Imaging phantom - Abstract
In Mammographic phantom images are usually used to study the quality of images obtained by determined mammographic equipment. The digital image treatment techniques allow carrying out an automatic analysis of the phantom image. Nowadays, the digital radiographic equipments are replacing the traditional film-screen equipments and it is necessary to update the parameters to guarantee the quality of the process. In this work we apply some techniques of digital image processing to compute a specific image quality indexes for mammographic phantoms, namely CIRS SP01 and CDMAM 3.4. to study the evolution of this parameter with different varying conditions of the mammographic equipment. The indexes are calculated from a scoring system based on a designed algorithm which analyses the phantom image by means of an automatic detection of the test objects in each phantom.
- Published
- 2009
- Full Text
- View/download PDF
23. Analysis of digital radiographic equipments with development of specific phantoms and software
- Author
-
B. Marín, Gumersindo Verdú, J. M. Campayo, Patricia Mayo Nogueira, and F. Rodenas
- Subjects
Computer science ,Image quality ,business.industry ,Contrast resolution ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,Image processing ,Imaging phantom ,DICOM ,Computer vision ,Artificial intelligence ,Computed radiography ,business ,Image resolution ,Digital radiography - Abstract
In this work we have designed some specific phantoms to study the obtained image of computerized and direct digital radiographic equipments to characterize the constancy of the imaging chain. The developed phantoms are applied for different radiographic digital devices, as conventional equipments with computed radiography (phosphor plate) and direct radiography (sensor) technology. These phantoms have specific characteristics for these systems, as different test zones for the analysis of the image quality. The test zones that are in these phantoms are low contrast objects, varying in diameter and size, for the threshold contrast resolution of the system, high resolution test for the limiting spatial resolution, dynamic step wedge for the dynamic range of grays of the system, homogeneity zone and alignment marks for position and size of radiation field. Additionally, we have developed a software based on automatical processing techniques to analyze the image obtained by the radiographic equipment with digital processing techniques as edge detector, morphological operators, statistical test for the detected combinations. The images have been acquired in DICOM format and they can be analyzed with objective parameters as an image quality index and the contrast detail curve. The design of these phantoms let the evaluation of a wide range of operating conditions of voltage, current and time of the digital radiographic equipments and the functioning of the image chain of the digital system applied to its quality control for image quality and radiation exposure.
- Published
- 2009
- Full Text
- View/download PDF
24. Declassification of radioactive liquid wastes generated in radio immune assay [corrected] (RIA) laboratories
- Author
-
M, Sancho, J M, Arnal, J I, Villaescusa, J M, Campayo, and G, Verdú
- Subjects
Radioisotopes ,Radioactive Waste ,Radioimmunoassay ,Ultrafiltration ,Medical Waste Disposal ,Laboratories, Hospital ,Medical Waste - Abstract
Radioactive liquid wastes of low-medium activity level are generated in radio immune assay (RIA) laboratories, which are also potentially infectious because of the pathogens from patient blood. The most common way of managing these wastes consists of a temporal storage, for partial radioactivity decay, followed by management by an authorised company. The object of this work is to study the viability of treating radioactive liquid wastes coming from RIA using membrane techniques in order to reduce their volume, which would mean an improvement from the radiological point of view and a decrease in management costs. This paper describes the results of some experiments carried out with RIA real wastes, by means of processes such as ultrafiltration and reverse osmosis. It has been proved that waste volume can be significantly reduced, obtaining a treated liquid that is free of pathogens and organic matter and with an activity level around the environmental background.
- Published
- 2006
25. Monte Carlo image reconstruction of a mammographic phantom
- Author
-
J. I. Villaescusa, S. Ferrer, M. Ramos, J. M. Campayo, and Gumersindo Verdú
- Subjects
Physics ,Kerma ,Optics ,Image quality ,business.industry ,Monte Carlo method ,Detector ,Variance reduction ,Iterative reconstruction ,business ,Wedge (geometry) ,Imaging phantom - Abstract
The aim of this study is the development of a methodology to reconstruct via Monte Carlo techniques the radiographic image of the CIRS 11 A (MAMMO PHANTOM SP01) phantom. This phantom is used in image quality assessment during quality control tests in breast screening locations and other health centers. The mammographic phantom is comprised of a reference point, a glandular tissue step wedge, contrast and resolution targets, and groups of microcalcifications and fibers. The MCNP radiation transport code (version 4c2) has been modified and recompiled to let use of a large number of tallies and detectors per input file, and an azimuthal directional source biasing. The output surface air kerma (OSAK) delivered by the X-rays has been scored employing a rectangular matrix of point detectors (F5 tally) under the phantom, simulating the image system. Some variance reduction techniques have been implemented to ensure that photons reach the detectors and that weight fluctuations were reduced. The characteristic curve of the film-scanner imaging system combination has been obtained throughout several experimental measures with an aluminium sensitometric wedge and Monte Carlo simulations. The reconstructed images agree with the range of values, indicating that this method would be suitable for training purposes, phantom designing or dose calculations.
- Published
- 2005
- Full Text
- View/download PDF
26. A mammographic phantom image reconstruction through Monte Carlo techniques
- Author
-
Miguel Ramos, J. M. Campayo, S. Ferrer, Enrico Padovani, and Gumersindo Verdú
- Subjects
Physics ,medicine.medical_specialty ,Pixel ,medicine.diagnostic_test ,business.industry ,Image quality ,Monte Carlo method ,Iterative reconstruction ,Imaging phantom ,Kerma ,medicine ,Dosimetry ,Mammography ,Computer vision ,Medical physics ,Artificial intelligence ,business - Abstract
Mammographic phantoms are employed during quality control test in breast screening locations and other health centres. These quality controls are performed to achieve the image quality required to detect breast abnormalities, ensuring the minimum risk to radiographied women. The aim of this study is the development of a methodology to reproduce the image of a mammogram during a routine exposure in a breast screening programme. In a first step, the CIRS 11A (MAMMO PHANTOM SP01) mammographic phantom has been simplified and modelled with the Monte Carlo transport code MCNP-4c2. Different tallies (F2 and F5) have been used to score the photon flux under the phantom, and a group of aluminium layers (99.9% purity) have been employed to reconstruct the characteristic curve, which transforms output air kerma in a grey-scale level. The code has been modified to produce photons in a semi-cone, allowing any polar and azimuthal angle. Furthermore, different tally bins have been introduced to count photons in each pixel of the final image, improving computer time simulations. The horizontal resolution target has been reproduced at different tube loadings and pixel pitches. The reconstructed images agree with the range of values, indicating that this method would be suitable for training purposes, phantom designing or dose calculations
- Published
- 2004
27. Evaluation of the index quality image analysing microcalcifications in digitized mammographic images
- Author
-
J. M. Campayo, P. Mayo, Gumersindo Verdú, F. Rodenas, and J.I. Villaescusa
- Subjects
Image quality ,Computer science ,business.industry ,Binary image ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,Image processing ,Image segmentation ,Digital image ,Image texture ,Digital image processing ,Computer vision ,Artificial intelligence ,business ,Feature detection (computer vision) - Abstract
A method has been developed to analyse the digital image quality of mammographic images by means of automatic process techniques. The techniques used for the digital image treatment are standard techniques as the image thresholding to detect objects, the regional growing for pixels pooling and the morphological operator application to determine the objects shape and size, etc. This study allows the obtention of information about the microcalcifications, that due to its small size and lowly contrast can be obtained very difficultly by direct observation. The final aim of this work is to obtain one or more parameters to characterize the quality image in an objective way. These parameters will serve to compare images obtained at different mammographic centers and also, to study the temporal evolution of the image quality produced by determined mammographic equipment.
- Published
- 2003
- Full Text
- View/download PDF
28. Preliminary Results of Early Assessment of Response with Perfusion-CT in Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib
- Author
-
I. Victoria, C. Nicolau, M.C. Sebastia, Begoña Mellado, O. Reig Torras, B. Paño, and M. Campayo
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Sunitinib ,Hematology ,urologic and male genital diseases ,medicine.disease ,Renal cell carcinoma ,Internal medicine ,Medicine ,In patient ,Radiology ,business ,Perfusion ,medicine.drug - Abstract
Poster: "ECR 2013 / C-1596 / Preliminary results of early assessment of response with perfusion-CT in patient with metastatic renal cell carcinoma treated with sunitinib" by: "A. D. Sotomayor1, B. Pano Brufau2, J. M. Gutierrez1, B. Mellado2, O. Reig2, M. C. Sebastia2; 1Barcelona, Barcelona/ES, 2Barcelona/ES"
- Published
- 2012
- Full Text
- View/download PDF
29. Association Between Insulin Resistance (Ir) and Pathologic Complete Response (Pcr) to Neoadjuvant Chemotherapy (Nac) Among No Diabetic Women with Localized Infiltrating Breast Cancer (Libc)
- Author
-
Pedro L. Fernández, Pere Gascón, L. Fernández-Morales, Montse Muñoz, M. Campayo, A. Armengol-Alonso, Ignasi Tusquets, M.A. Segui-Palmer, Sonia Servitja, and X. González-Farré
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Insulin ,Hematology ,medicine.disease ,Basal (phylogenetics) ,Breast cancer ,Insulin resistance ,Internal medicine ,Diabetes mellitus ,medicine ,Metabolic syndrome ,Prospective cohort study ,business ,Neoadjuvant therapy - Abstract
Aim: The IR has been associated with increased risk of breast cancer (BC) and as a poor prognostic factor for relapse and survival. There is a lack of prospective studies that have reviewed the impact of IR across the NAC time and the likelihood of pCR. We determined the association between IR by HOMA2 (homeostasis model assessment) and pCR in LIBC. Methods: It was a prospective cohort, multicenter study. From 2012 to 2013, 64 patients were enrolled. Metabolic syndrome (MS) diagnosis was made by ATP III criteria. Insulin and glucose were measured at baseline and every 3 weeks during NAC. The IR was calculated by HOMA2 –IR.® Cut off value to define IR: HOMA2 ≥1.9. pCR (breast + nodes) was defined as no residual IBC. Results: Median age was 49 years. Axillary nodes were involved in 37 (57.8%). cTNM stage was II 50 (78.1%) and III 14 (21.8%). pCR (full cohort) was 37.5%. pCR in luminal A/B-like, triple negative and HER2 was 15.6%, 61.1% and 57.1% respectively. 25% had MS at baseline and up to 40% (final evaluation). At baseline 29 (45.3%) had IR and in final 34 (53.1%) (p = 0.005). We observed a gradual and almost linear increase of IR during the NAC time (p = 0.019). The group without IR (baseline) had a higher likelihood of pCR (HR 3.1, 95% CI 1.3-7.3). In the pCR group the HOMA2 remained below or slightly above 1.9 and with no changes over time (p = 0.225). Inversely in the no pCR group the IR increased over time and almost with a linear trend (p = 0.013). In a repeated measures analysis of HOMA2 over NAC time in the three biological subgroups, differences were observed only in luminal-like (p = 0.044). Comparing quartiles (Q1-2 vs Q3-4), basal insulin (p =0.018) and basal HOMA2 (p = 0.032) were significantly associated with pCR. In an adjusted logistic regression analysis for pCR, the IR remained as an independent factor for pCR (p = 0.018). Conclusions: We found a strong association between the status of IR and the likelihood of pCR in neoadjuvant setting of BC. To our knowledge this is the first prospective study describing the natural history of IR across time of the NAC. The IR increased over time of the NAC and the pCR likelihood is inversely associated with IR. Our findings suggest that the increase in central adiposity during NAC time produces a greater insulin resistance and thereby a cell proliferative environment resulting in a lower response to NAC. Disclosure: All authors have declared no conflicts of interest.
- Published
- 2014
- Full Text
- View/download PDF
30. 693: Intrinsic resistance to sunitinib in clear cell renal cell carcinoma: A gene expression analysis
- Author
-
Begoña Mellado, Juan José Lozano, B. Gonzalez, O. Reig, Mercedes Marín-Aguilera, Carme Mallofré, M. Campayo, and Pere Gascón
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Sunitinib ,Intrinsic resistance ,medicine.disease ,Clear cell renal cell carcinoma ,Internal medicine ,Expression analysis ,medicine ,business ,Gene ,medicine.drug - Published
- 2014
- Full Text
- View/download PDF
31. Impact of Body Mass Index (BMI) on Disease Free Survival and Likelihood of Pathologic Complete Response in Patients with Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy
- Author
-
Montse Muñoz, A. García-Herrera, X. Caparros, Ana Arance, X. González-Farré, Pedro L. Fernández, Blanca Farrús, I. Alonso, M. Campayo, and A. Armengol-Alonso
- Subjects
Oncology ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Confounding ,Hematology ,Overweight ,medicine.disease ,Breast cancer ,Internal medicine ,medicine ,Underweight ,medicine.symptom ,business ,Prospective cohort study ,Body mass index ,Pathological - Abstract
Background The BMI is a clinical parameter that although not perfect is often used to measure adiposity. In breast cancer there are multiple studies indicating that overweight/obesity (O/O) is related with lower survival and increased risk of relapse. It has been also reported less likely to achieve a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in O/O patients. Methods We retrospectively reviewed the records of 108 patients diagnosed with invasive locally advanced breast cancer (ILABC) who had been treated with NAC (anthracycline + taxane ± trastuzumab). The aim of our study was to review the impact of BMI on the pCR and the possibility of recurrence. pCR was defined as the criterion of strict pCR breast+nodes. Results From 2004 to 2011, 108 patients received NAC. Based on their weight and height at baseline we divided into two groups; group 1: underweight/normal (BMI Conclusions Despite the retrospective nature of this study we can conclude that the patients with ILABC and O/O have a high risk for relapse and decreased response to NAC. It requires well-designed prospective studies to control confounding factors (dose intensity, chemotherapy regimens, changes in BMI) to get clear answers of these associations. Disclosure All authors have declared no conflicts of interest.
- Published
- 2012
- Full Text
- View/download PDF
32. Dosimetric capabilities of the Iview GT portal imager using MCNP5 Monte Carlo simulations
- Author
-
Belén Juste, J. M. Campayo, Gumersindo Verdú, Rafael Miró, and Sergio Diez
- Subjects
Physics ,Attenuator (electronics) ,Photons ,Pixel ,business.industry ,Phantoms, Imaging ,Radiotherapy Planning, Computer-Assisted ,X-Rays ,Monte Carlo method ,Radiotherapy Dosage ,Equipment Design ,Photon energy ,Radiation Dosage ,Imaging phantom ,Optics ,Region of interest ,Ionization chamber ,Dosimetry ,Humans ,Computer Simulation ,Radiotherapy, Intensity-Modulated ,business ,Radiometry ,Monte Carlo Method ,Algorithms - Abstract
This work is focused on developing a methodology to obtain portal dosimetry with an amorphous silicon Electronic Portal Image Device (a-Si EPID) used in radiotherapy by means of Monte Carlo simulations and experimental measures. Pixel intensity values from portal images have been compared with dose measured from an ionization chamber and dose calculated from Monte Carlo simulations. To this end, several images were acquired with the Elekta iView GT EPID using an attenuator phantom slab (10 cm thickness of solid water) and a 6 MeV photon energy beam with different monitor units settings (MU). The average pixel value in a region of interest (ROI) centered at the beam for each image was extracted and compared to dose measures performed with an ionization chamber. These parameters were found to be linearly related with the number of monitor units. Since MCNP5 simulations allow calculating the deposited dose in the ROI within the phosphor layer of the EPID model, we could compare the portal dose with the simulated transit dose in order to perform a treatment control.
33. Phantom development for constancy and acceptance test for digital radiographic equipment
- Author
-
A. Pascual, P. Mayo, Gumersindo Verdú, F. Rodenas, J. M. Campayo, and B. Marín
- Subjects
Nuclear and High Energy Physics ,Standard test image ,Radiographic equipment ,business.industry ,Image quality ,Computer science ,020209 energy ,Contrast resolution ,02 engineering and technology ,Condensed Matter Physics ,Imaging phantom ,020303 mechanical engineering & transports ,0203 mechanical engineering ,Nuclear Energy and Engineering ,Digital image processing ,0202 electrical engineering, electronic engineering, information engineering ,Computer vision ,Artificial intelligence ,business ,Image resolution ,Digital radiography - Abstract
The development of specific phantoms to study the image obtained by computerized and direct digital radiographic equipment is the objective of this work to characterize the physical properties of the image chain. We have developed a specific phantom, named RACON, that is applied to an acceptance and constancy test to assess the image quality of digital radiographic equipment. This phantom has been designed with different test objects recommended by international and national associations (IEC-61223-2-9, RD 1976―1999) as low-contrast objects varying in diameter and size for threshold contrast resolution, a high-resolution test for the limiting spatial resolution, a dynamic step wedge for the dynamic range of the system, and a homogeneity zone and alignment marks for the position and size of the radiation field. Furthermore, we have developed specific software to analyze automatically and objectively the phantom images. The algorithms are based on digital image processing techniques, and they have been specifically designed for each test object in the phantom. The developed phantom is sensitive enough to the operating conditions of the radiographic digital system, and the automatic image evaluation allows the objective study of the global state of the image system.
34. Linear accelerator photon spectra reconstruction using a mixed experimental Monte Carlo method
- Author
-
Rafael Miró, J. M. Campayo, Belén Juste, Sergio Diez, and Gumersindo Verdú
- Subjects
Physics ,Nuclear and High Energy Physics ,Photon ,business.industry ,Physics::Medical Physics ,Monte Carlo method ,Bremsstrahlung ,Isocenter ,Monte Carlo method for photon transport ,Condensed Matter Physics ,Linear particle accelerator ,Imaging phantom ,Optics ,Nuclear Energy and Engineering ,business ,Beam (structure) - Abstract
The work focuses on reconstructing, by means of a scatter analysis method, the primary beam photon spectrum of a linear accelerator. This technique is based on irradiating the isocenter of a rectangular block made of methacrylate placed at 100 cm from the source and measuring scattered particles around the plastic at several specific positions with different scatter angles. The MCNP5 Monte Carlo code has been used to simulate the particle transport of monoenergetic beams and register the scatter measurement after contact with the attenuator. Measured ionization values are input necessary for calculating the spectrum as the sum of monoenergetic individual energy bins using the Schiff bremsstrahlung model. The measurements have been made in an Elekta Precise linac using a 6-MeV photon beam. Relative depth and profile dose curves calculated in a water phantom using the reconstructed spectrum agree with the experimentally measured dose data to within 5%.
35. SPAZO2 (SOGUG): Validation of the international metastatic database consortium (IMDC) prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib (1stPz) in metastatic renal cell carcinoma (mRC)
- Author
-
I. Chirivella Gonzalez, José Muñoz-Langa, R. Luque Caro, R. García Domínguez, I. García Carbonero, M. Campayo Guillaumes, R.D. García Marrero, M. Lázaro, C. Molins Palau, J. J. Garcia, M. Sereno Moyano, J.A. Arranz Arija, Á. Rodríguez Sánchez, C. Suarez Rodriguez, B. Pérez-Valderrama, G. De Velasco, E. Martinez Ortega, U. Anido Herranz, M.A. Gonzalez Del Alba Baamonde, and A. Hernández Jorge
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Hematology ,medicine.disease ,Pazopanib ,Prognostic classification ,Renal cell carcinoma ,Internal medicine ,medicine ,Line (text file) ,business ,medicine.drug
36. Image quality assessment of digital dental radiography systems with specifically developed phantom and software
- Author
-
P. Mayo, Gumersindo Verdú, F. Rodenas, A. Pascual, J. M. Campayo, and B. Marín
- Subjects
Nuclear and High Energy Physics ,Dental radiography ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Computer science ,Image quality ,Radiography ,Condensed Matter Physics ,Imaging phantom ,Software ,Nuclear Energy and Engineering ,medicine ,Medical physics ,Computed radiography ,business ,Quality assurance ,Digital radiography - Abstract
The purpose of this work is to assess the image quality of dental digital systems with computed radiography (phosphor plate) and direct radiography (charge-coupled-device sensor), by developing a s...
37. Study of digital mammographic equipments by phantom image quality
- Author
-
F. Rodenas, Gumersindo Verdú, P. Mayo, J. I. Villaescusa, and J. M. Campayo
- Subjects
Quality Control ,Engineering ,Image quality ,media_common.quotation_subject ,Sensitivity and Specificity ,Imaging phantom ,medicine ,Mammography ,Computer vision ,Quality (business) ,Sensitivity (control systems) ,Image resolution ,Digital radiography ,media_common ,Measure (data warehouse) ,medicine.diagnostic_test ,business.industry ,Phantoms, Imaging ,Reproducibility of Results ,Equipment Failure Analysis ,Radiographic Image Enhancement ,Radiographic Image Interpretation, Computer-Assisted ,Artificial intelligence ,business ,Algorithms - Abstract
Nowadays, the digital radiographic equipments are replacing the traditional film-screen equipments and it is necessary to update the parameters to guarantee the quality of the process. Contrast-detail phantoms are applied to digital radiography to study the threshold contrast-detail sensitivity at operation conditions of the equipment. The phantom that is studied in this work is CDMAM 3.4. One of the most extended indexes to measure the image quality in an objective way is the image quality figure (IQF). The aim of this work is to study the image quality of different images contrast-detail phantom CDMAM 3.4, carrying out the automatic detection of the contrast-detail combination and to establish a parameter which characterize in an objective way the mammographic image quality. This is useful to compare images obtained at different digital mammographic equipments to study the functioning of the equipments that facilitates the evaluation of image contrast and detail resolution.
38. Photon spectra calculation for an Elekta linac beam using experimental scatter measurements and Monte Carlo techniques
- Author
-
B. Juste, Gumersindo Verdú, R. Miro, Sergio Diez, and J. M. Campayo
- Subjects
Photon ,Physics::Medical Physics ,Monte Carlo method ,Linear particle accelerator ,law.invention ,Optics ,law ,Humans ,Scattering, Radiation ,Computer Simulation ,Radiometry ,Ions ,Physics ,Photons ,Models, Statistical ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Spectrum Analysis ,Bremsstrahlung ,Reproducibility of Results ,Isocenter ,Radiotherapy Dosage ,Particle accelerator ,Monte Carlo method for photon transport ,Equipment Design ,Particle Accelerators ,business ,Monte Carlo Method ,Algorithms ,Beam (structure) - Abstract
The present work is centered in reconstructing by means of a scatter analysis method the primary beam photon spectrum of a linear accelerator. This technique is based on irradiating the isocenter of a rectangular block made of methacrylate placed at 100 cm distance from surface and measuring scattered particles around the plastic at several specific positions with different scatter angles. The MCNP5 Monte Carlo code has been used to simulate the particles transport of mono-energetic beams to register the scatter measurement after contact the attenuator. Measured ionization values allow calculating the spectrum as the sum of mono-energetic individual energy bins using the Schiff Bremsstrahlung model. The measurements have been made in an Elekta Precise linac using a 6 MeV photon beam. Relative depth and profile dose curves calculated in a water phantom using the reconstructed spectrum agree with experimentally measured dose data to within 3%.
39. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
- Author
-
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Prelaj A, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar Nana F, Ponce S, Albarrán-Artahona V, Dal Maso A, Spotti M, Mielgo X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier JB, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Mezquita L, and Planchard D
- Subjects
- Humans, Female, Male, Retrospective Studies, Aged, Prognosis, Middle Aged, Aged, 80 and over, Adult, Antineoplastic Agents, Immunological therapeutic use, Survival Rate, Neutrophils pathology, Chemoradiotherapy methods, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms pathology, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Lung Neoplasms therapy, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal administration & dosage
- Abstract
Introduction: The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) and LDH, is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-small-cell lung cancer (NSCLC). We aimed to assess baseline LIPI correlation with durvalumab consolidation outcomes in the locally advanced setting., Material and Methods: Multicentre retrospective study (330 patients) with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and December 2020; 65 patients treated with chemo-radiotherapy only. Baseline LIPI characterized 3 groups: good (dNLR≤3+LDH≤ULN), intermediate (dNLR>3/LDH>ULN) and poor (dNLR>3+LDH>ULN). Primary endpoint was overall survival (OS)., Results: In the durvalumab cohort, median age was 67 years, 95% smokers, 98% with a performance status of 0-1; 60% had nonsquamous histology and 16% a PD-L1 expression <1%. Radiotherapy was delivered concurrently in 81%. LIPI was evaluable in 216 patients: 66% good, 31% intermediate, 3% poor. LIPI significantly correlated with median OS (median follow-up: 19 months): 18.1 months vs. 47.0 months vs. not reached in poor, intermediate and good LIPI groups, respectively (P = .03). A trend between objective response rate and LIPI groups was observed: 0% vs. 41% vs. 45%, respectively (P = .05). The pooled intermediate/poor LIPI group was associated with shorter OS (HR 1.97; P = .03) and higher risk of progressive disease (OR 2.68; P = .047). Survivals and response were not influenced in the control cohort., Conclusion: Baseline LIPI correlated with outcomes in patients with locally advanced NSCLC treated with durvalumab consolidation, but not in those who only received chemo-radiotherapy, providing further evidence of its prognostic and potential predictive role of ICI benefit in NSCLC., Competing Interests: Disclosure VAA: Lectures and educational activities: Bristol-Myers Squibb, AstraZeneca, MSD; Travel, Accommodations, Expenses: Takeda, Sanofi, Janssen; RL: Personal fees: AstraZeneca, Bristol-Myers Squibb. Travel, Accommodations: Roche, Italfarmaco; RLC: Consulting, advisory role or lectures: Amgen, Bristol-Myers Squibb, Pierre-Fabre, Boehringer Ingelheim, Novartis, Roche. Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pierre-Fabre, MSD, Novartis, Pfizer, Roche, Takeda. Clinical trials research: AstraZeneca, Roche. Travel, Accommodations, Expenses: Roche, Novartis, Takeda, Boehringer Ingelheim; JBB: Reports grants and personal fees from Roche and Pfizer, and personal fees from MSD, BMS, AstraZeneca, Boehringer-Ingelheim, Sanofi, and Novartis, outside the submitted work; SP: Consulting, advisory role or lectures: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Roche, Amgen, Takeda (outside the submitted manuscript); MT: Travel, accommodation, expenses: Roche, Bristol-Myers Squibb, AstraZeneca, Takeda, Eli Lilly. Honoraria as medical writer: Novartis, Amgen, MSD. None related to the current manuscript; MS: Speaker, Advisory Role: Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi Avemtis, Siemens Healthineers, Takeda; Research support (institutional): Amgen, BMS, Dracen Pharmaceuticals, Janssen, Novartis, Pfizer, Siemens Healthiness; EN: has participated in lectures and advisory boards from Roche, Bristol Myers Squibb, Merck Sharp & Dohme, Merck Serono, Pfizer, Lilly, Amgen, Boehringer Ingelheim, AstraZeneca, Takeda, Sanofi and Bayer. E. N. has received research funding support from Pfizer, Roche, Merck Serono, Bristol Myers Squibb and Nanostring; GL: Honorary from Boehringer Ingelheim, Blueprint Medicines, AstraZeneca, Merck, Janssen; Consulting and advisory role from Pfizer and AstraZeneca; Research funding from AstraZeneca, Lucence, Xilis, Merck Sharp and Dohme, EMD Serono, Blueprint Medicines, Tesaro, Vavarian Nordic, Novartis, G1 Therapeutics. AdaptImmune, BMS, GSK, Abbvie, Rgenix, Pfizer, Roche, Genentech, Lilly, Janssen; travel, accommodations and expenses from Boehringer Ingelheim, Pfizer, Squibb Sons, Janssen, Seattle Genetics, Celgene, Ibsen, Pharmacyclocs, Merck, AstraZeneca, Seagen; DS: Consulting, advisory role: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Merck Sharp & Dohme, Sanofi. Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Roche, Merck Sharp & Dohme. Principal Investigator in clinical trial sponsored by Bristol-Myers Squibb, Merck Sharp & Dohme, Eli Lilly. Travel, Accommodations: AstraZeneca, Roche, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer; RGC: Consulting, advisory role or lectures from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Takeda, Janseen, MSD, Roche, Pfizer, Eli Lilly, Amgen, Sanofi; honoraria (self) from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Roche, MSD, Takeda, Eli Lilly, Novartis; clinical trials research from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis; VB: Consulting, advisory role: AstraZeneca, Bristol-Myers Squibb, MSD, Merck, Novartis, Pfizer, Roche. Clinical trials research: AstraZeneca, MSD, Roche; MC: Advisory or Consultancy role: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, EUSA Pharma, Lilly, Roche. Honoraria, lectures: Abbot, AstraZeneca, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Merck, Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche, Takeda. Travel expenses: Ipsen, Lilly, Merck, Pfizer, Pierre Fabre. Institutional financial interests: Astra Zeneca, Merck, Pfizer, Roche; BB: Sponsored Research at Gustave Roussy Cancer Center, Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma; DP: Consulting, advisory role or lectures: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. Clinical trials research: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo. Travel, Accommodations, Expenses: AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer; LM: Research grant/Funding (self): Bristol Myers Squibb, Boehringer Ingelheim, Amgen, Stilla, Inivata; Advisory/Consultancy: Roche Diagnostics, Takeda; Honoraria (self): Bristol Myers Squibb, Tecnofarma, Roche; Travel/Accommodation/Expenses: Roche, Boehringer Ingelheim, Takeda, AstraZeneca. The remaining authors declare no conflict of interest., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
40. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
- Author
-
de Velasco G, Alonso-Gordoa T, Rodríguez-Vida A, Anguera G, Campayo M, Pinto Á, Ortega EM, Gallardo E, Núñez NF, García-Carbonero I, Reig O, Méndez-Vidal MJ, Fernández-Calvo O, Cassinello NV, Torregrosa D, López-Martín A, Rosero A, Valiente PG, de España CG, Climent MA, Santasusana MD, Sánchez ÁR, González IC, Afonso R, García Del Muro X, Casinello J, Fernández-Parra EM, García Sánchez L, Afonso J, Polo SH, and Asensio Ú
- Subjects
- Humans, Middle Aged, Sunitinib therapeutic use, Retrospective Studies, Indoles therapeutic use, Pyrroles therapeutic use, Carcinoma, Renal Cell drug therapy, Carcinoma, Renal Cell secondary, Antineoplastic Agents therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology
- Abstract
Introduction: The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are poorly known. The characteristics of these patients could reveal previously undetected associations with clinical variables., Patients and Methods: This observational, retrospective study (ATILA) used data from a registry of patients with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018 in Spain., Results: Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age was 58.5 years (range, 32-81). Most patients (79.0%) had clear cell histology and had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib was 28.2 months (IQR, 16.7-41.0) and the median time to CR was 10.9 months (IQR, 7.2-19.3). After a median follow-up of 8 years (range, 3-13 years), the median PFS was not reached. The overall median duration of complete response was 64.1 months (IQR, 32.2-99.4). The tolerance and safety profile of sunitinib was consistent with previous reports., Conclusion: Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis site or histology type, with 75% of patients remaining in CR after 10 years., Clinicaltrials: gov: NCT03916458., Competing Interests: Disclosures G.d.V. received research grants from Pfizer, Roche, and Ipsen; consulting or honoraria fees from Ipsen, Pfizer, Roche, Bayer, Astellas, BMS, MSD and Merck. T.A.G. received research grants from Pfizer, Roche, and Ipsen; consulting fees from Ipsen, Pfizer, Roche, Sanofi, Bayer, Astellas, Janssen-Cilag, BMS, and EISAI; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Ipsen, Pfizer, Eisai, and Merck; and support for attending meetings and/or travel from Pfizer, Sanofi, BMS, and IPSEN. A.R.-V. served in advisory boards for MSD, Pfizer, BMS, Astellas, Janssen, Bayer, Clovis and Roche; received honoraria or travel expenses from Pfizer, MSD, Astellas, BMS, Janssen, Astra Zeneca, Roche, Bayer, and Sanofi Aventis; and research funding from Takeda, Pfizer, and Merck. G.A.P. served in speaker bureaus for Ipsen, BMS, Roche, and Janssen. M.C. served in advisory or consultancy roles for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, EUSA Pharma, Lilly, Roche; received honoraria for lectures for Abbot, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Novartis, Pfizer, Pierre Fabre, Roche; holds institutional financial interests in Astra Zeneca, Merck, Pfizer, Roche, and received travel expenses from Ipsen, Lilly, Merck, Pfizer, and Pierre Fabre. A.P. received research grants from Pfizer and BMS; advisory boards/speaker fees from Pfizer, BMS, Ipsen, Roche, Merck, MSD, Janssen, Astellas, Bayer, Sanofi; and travel expenses from Pfizer, BMS, Janssen and Roche. E.G. received grant support from Astellas, Janssen, Sanofi, Bayer, Ipsen, Ferrer, Pfizer, Roche, GSK and BMS; consulting fees from Sanofi, Janssen, Astellas, Bayer, Ipsen, Pfizer, Roche, Novartis, Eisai, EUSA Pharma, BMS, AstraZeneca, Merck, Rovi, Daiichi Sankyo and Techdow; payment or honoraria for lectures, presentations, speakers’ bureaus, man-uscript writing, or educational events from Astellas, Janssen, Sanofi, Bayer, Ipsen, Pfizer, Roche, BMS, Rovi, Daiichi Sankyo, Leo Pharma, Menarini, Eisai, MSD, Boehringer Ingelheim, Merck, EUSA Pharma and Novartis; support for attending meetings and/or travel from As-tellas, Janssen, Sanofi, BMS, Bayer, Ipsen, Roche, Novartis, Pierre Fabre, Pfizer and Eisai. N.F.N. received support from Roche, BMS, Boehringuer, Sanofi, Bayer, Astra Zeneca, Janssen, MSD, Lilly, Pfizer and IPSEN. I.C.-G. participated in advisory boards of Pfizer, EISAI and BMS. O.R. had consulting or advisory roles with BMS, EISAI, Ipsen; received travel and accommodations support from Ipsen and Pfizer. M.J.M. received honoraria and /or travel support from Janssen-Cilag, Bayer healthcare, Sanofi Aventis, Astellas Medivation, Roche, Ipsen, EISAI, Novartis and Pfizer; advisory boards and speaking for: Pfizer, Astellas, Roche, Ipsen, BMS, Eusa Pharma, Sanofi, Novartis, Janssen andPierre Fabre. N.V.C. received consultant fees from Janssen; speaking fees from Sanofi, Astra Zeneca, Astellas, Janssen, Roche, MSD, Ipsen; and travel support from Pfizer, Pierre Fabre, BMS. A.L.M. received support for attending meetings from Roche and MSD. C.G.d.E. has held consultant or advisory roles with Janssen, Sanofi, Bayer, Astellas; speaking roles from Janssen, Sanofi, Bayer, Astellas, Roche, Ipsen, Pfizer; and other support from Janssen, Sanofi and Roche. M.A.C. has held consulting or advisory role with BMS, MSD, Bayer, EUNSA, Pfizer, Roche, Janssen, Pierre Fabre, Ipsen; received travel expenses from Janssen, Astellas, Roche, Ipsen, and MSD. A.R.S. held consulting or advisory roles for Roche, Bristol, Sanofi, Merck, Ipsen and Eisai. I.C.G. has served as consultant or advisory board to Pzifer, Bristol-Myers Squibb, Ipsen, Roche and EusaPharma; has served as speaker to Pfizer, Bristol-Myers Squibb and Ipsen; and received travel and/or accommodation grants from Pfizer. R.A. has participated in advisory boards for Pfizer, Roche, Sanofi and Servier. X.G.d.M. has participated in advisory boards or as invited speaker for Astellas, BMS, Ipsen, Roche, Eusa Pharma, Eisai, Pfizer and Pharmamar. J.C. reports support from Janssen, Roche, AstraZéneca, Astellas, BMS, Pfizer, Sanofi, and Novartis. J.A. received advisory boards/speaker fees from Novartis, Pfizer, Merck, Roche, BMS; and travel and accommodations from AstraZeneca, BMS, Pfizer, Astellas and Sanofi. S.H.P. participated in advisory boards and as speaker for GSK, Clovis, Astra-Zeneca/MSD and Pfizer. Ú.A. is an employee of Pfizer. All other authors report no conflicts of interests., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
41. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations.
- Author
-
Riudavets M, Auclin E, Mosteiro M, Dempsey N, Majem M, Lobefaro R, López-Castro R, Bosch-Barrera J, Pilotto S, Escalera E, Tagliamento M, Mosquera J, Zalcman G, Aboubakar-Nana F, Ponce S, Dal Maso A, Spotti M, Mielgo-Rubio X, Mussat E, Reyes R, Benítez JC, Lupinacci L, Duchemann B, De Giglio A, Blaquier J, Audigier-Valette C, Scheffler M, Nadal E, Lopes G, Signorelli D, Garcia-Campelo R, Menis J, Bluthgen V, Campayo M, Recondo G, Besse B, Planchard D, and Mezquita L
- Subjects
- Aged, Antibodies, Monoclonal, ErbB Receptors genetics, Genomics, Humans, Protein-Tyrosine Kinases therapeutic use, Proto-Oncogene Proteins genetics, Retrospective Studies, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology
- Abstract
Introduction: Durvalumab is the standard-of-care as consolidation therapy after chemo-radiotherapy in stage III unresectable non-small cell lung cancer (NSCLC); however, its activity across patients with NSCLC harbouring driver genomic alterations (dGA) is poorly characterised., Material and Methods: Multicentre retrospective study including patients with stage III unresectable NSCLC treated with durvalumab after chemo-radiotherapy between April 2015 and October 2020 at 26 centres in Europe and America. Clinical and biological data were collected; dGA included: EGFR/BRAF/KRAS mutations (m) and ALK/ROS1 rearrangements (r). We evaluated progression-free survival (PFS) and overall survival (OS) based on dGA., Results: Out of 323 patients included, 43 patients had one dGA: KRASm (n = 26; 8 G12C), EGFRm (n = 8; 6 del19/ex21), BRAFm (n = 5; 4 V600E) and ALKr (n = 4). The median age was 66 years [39-84], gender ratio 1:1, with 98% performance status (PS) 0-1 and 19% non-smokers; 88% had adenocarcinoma. PD-L1 was positive in 85% (n = 4 missing). In the whole cohort, the median PFS was 17.5 months (mo.) (95% CI, 13.2-24.9) and median OS 47 mo (95%CI, 47-not reached [NR]). No statistically significant differences in terms of the median PFS were observed between patients with dGA vs. non-dGA: 14.9 mo (95% CI, 8.1-NR) vs. 18 mo. (95% CI, 13.4-28.3) (P = 1.0); however, when analysed separately: the median PFS was NR (11.3-NR) in the KRASm G12C vs. 8.1 mo (5.8-NR) in the EGFRm del19/ex21 vs. 7.8 mo (7.7-NR) in the BRAFm V600E/ALKr (P = 0.02)., Conclusions: We observed limited activity of durvalumab consolidation in patients with stage III unresectable NSCLC with EGFR/BRAFm and ALKr but not for those harbouring KRASm. Larger prospective studies are needed to confirm these findings., Competing Interests: Conflict of interest statement MMj: advisory and consultancy honoraria from Roche, Merck, BristolMyers Squibb, AstraZeneca, Amgen, Boehringer, Sanofi and Takeda; speaker honoraria from Roche, Merck, Bristol-Myers Squibb, AstraZeneca, Bayer, Amgen, Pfizer and Boehringer; grants from AstraZeneca and BristolMyers Squib, and travel/accommodation expenses from Roche, Merck and Lilly. RLC: honoraria from Kyowa Kirin, Pierre-Fabre, Takeda, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Roche, Merck Serono, Pfizer; consulting or advisory role from Roche, Astra-Zeneca, Boehringer Ingelheim, Aristo, Novartis; research funding from Roche, Bristol-Myers Squibb, MSD, Boehringer Ingelheim, AstraZeneca. JBB: grants and personal fees from Roche-Genentech, Pfizer, MSD, BMS, Astrazeneca, Novartis, Boehringer-Ingelheim, Vifor, Sanofi, LEO Pharma, outside the submitted work. SP: Consulting, advisory role or lectures from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Roche, Amgen. MT: travel grants from Roche, Bristol-Myers Squibb, AstraZeneca, Takeda; honoraria as medical writer from Novartis, Amgen. GZ: research grants from Roche-France, Bristol-Myers Squibb, and Takeda outside of the submitted work; perceived fees from Bristol-Myers Squibb, AstraZeneca, Pfizer, and Boehringer Ingelheim outside the submitted work; and reimbursement for international meetings assistance from AbbVie, Merck Sharp & Dohme, AstraZeneca, Bristol-Myers Squibb, and Roche-France. XM-R: Research grant funding from Brystol-Myers Squibb; consulting, advisory role or lectures from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim; honoraria (self) from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Roche, MSD; clinical trials research from Boehringer Ingelheim, Pfizer, Roche, Abbvie; travel, accommodations and expenses from Roche, Pfizer, Brysto-Myers Squibb. JB: educational grants by AMGEN. MSch: speaker and advisory role honoraria, travel accommodations from AMGEN, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Novartis, Pfizer, Roche, Takeda; personal research support from AMGEN, Dracen Pharmaceuticals, Siemens Healthineers; institutional research support from Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Novartis, Pfizer, Roche. EN: research support from Roche, Merck Serono, Bristol Myers Squibb and Pfizer and participated in advisory boards or lectures from Bristol Myers Squibb, Merck Serono, Merck Sharpe & Dohme, Lilly, Roche, Pfizer, Takeda, Bayer, Boehringer Ingelheim, Amgen and AstraZeneca. DS: Consulting, advisory role, honoraria from AstraZeneca, Merck Sharp & Dohme, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Eli Lilly; travel grants from Roche. RGC: Consulting, advisory role or lectures from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Takeda, Janseen, MSD, Roche, Pfizer, Eli Lilly, Amgen, Sanofi; honoraria (self) from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer, Roche, MSD, Takeda, Eli Lilly, Novartis; clinical trials research from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis. JMe: Advisory Boards/Honoraria/Speakers’ fee/Consultant for Astra-Zeneca, Boeringher Ingelheim, BMS, Roche, MSD; travel grants from Astra-Zeneca, Boeringher Ingelheim, BMS, Ipsen, Roche, MSD. VB: Clinical trial research from AstraZeneca, Roche, MSD; advisory role/consulting/speaker from Pfizer, MSD, AstraZeneca, Roche, Bristol, Merck, Takeda. MC: Advisory or Consultancy role from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, EUSA Pharma, Lilly, Roche; honoraria, lectures from Abbot, Bristol-Myers Squibb, EUSA Pharma, Ipsen, Novartis, Pfizer, Pierre Fabre, Roche; travel, expenses from Ipsen, Lilly, Merck, Pfizer, Pierre Fabre; institutional financial interests from Astra Zeneca, Merck, Roche, Pfizer. GR: consulting, advisory role or lectures from AstraZeneca, Bayer, Bristol-Myers Squibb, Janssen, Merck Sharp & Dome, Pfizer, Roche, Takeda; sponsored Research Amgen and Janssen. BB: sponsored research at Gustave Roussy Cancer Centre Abbvie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma. DP: consulting, advisory role or lectures from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; honoraria from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche; clinical trials research from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daiichi Sankyo; travel, accommodations, expenses from AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer. LM: research grant/Funding (self) from Bristol Myers Squibb, Boehringer Ingelheim, Amgen, Stilla, Inivata; advisory/consultancy from Roche, Takeda; honoraria (self) from Bristol Myers Squibb, Roche, Takeda, AstraZeneca; travel/Accommodation/Expenses from Roche, Bristol Myers Squibb, Takeda, AstraZeneca; non-remunerated activity/ies from AstraZeneca. MR, EA, MMo, ND, EE, RL, JMo, FA, SP, AD, MSp, EM, RR, JCB, LL, BD, AdG, CAV and GL declare no conflicts of interest., (Copyright © 2022. Published by Elsevier Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
42. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
- Author
-
Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, and Climent MA
- Subjects
- Axitinib therapeutic use, Female, Humans, Male, Retrospective Studies, Sunitinib, Carcinoma, Renal Cell pathology, Kidney Neoplasms pathology
- Abstract
Background: Axitinib monotherapy obtained approval in pre-treated mRCC patients and recently in combination with pembrolizumab or avelumab in the first-line setting. However, patient profiles that may obtain increased benefit from this drug and its combinations still need to be identified., Patients and Methods: Retrospective multicentre analysis describing clinical characteristics associated with axitinib long-responder (LR) population by comparing two extreme-response sub-groups (progression-free survival [PFS] ≥9 months vs. disease progression/refractory patients [RP]). A multivariate logistic-regression model was used to analyse clinical factors. Efficacy and safety were also analysed., Results: In total, 157 patients who received axitinib in second or subsequent line were evaluated (91 LR and 66 RP). Older age at start of axitinib and haemoglobin levels > LLN were independent predictive factors for LR in multivariate analyses. In LR patients, median (m) PFS was 18.1 months, median overall survival was 36.0 months and objective response rate (ORR) was 45.5%. In 59 LR patients receiving axitinib in second-line, mPFS was 18.7 months, mOS was 44.8 months and ORR was 43.9%. mOS was significantly longer in second line compared to subsequent lines (44.8 vs. 26.5 months; P = .009). In LR vs. RP, mPFS with sunitinib in first-line was correlated with mPFS with axitinib in second-line (27.2 vs. 10.9 months P < .001). The safety profile was manageable and consistent with known data., Conclusions: This study confirms the long-term benefits of axitinib in a selected population, helping clinicians to select the best sequential approach and patients who could obtain a greater benefit from axitinib., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
43. Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal Cancer.
- Author
-
Benitez JC, Campayo M, Díaz T, Ferrer C, Acosta-Plasencia M, Monzo M, Cirera L, Besse B, and Navarro A
- Abstract
Preoperative chemoradiotherapy (CRT) is a standard treatment for locally advanced rectal cancer (RC) patients, but its use in non-responders can be associated with increased toxicities and resection delay. LincRNA-p21 is a long non-coding RNA involved in the p53 pathway and angiogenesis regulation. We aimed to study whether lincRNA-p21 expression levels can act as a predictive biomarker for neoadjuvant CRT response. We analyzed RNAs from pretreatment biopsies from 70 RC patients treated with preoperative CRT. Pathological response was classified according to the tumor regression grade (TRG) Dworak classification. LincRNA-p21 expression was determined by RTqPCR. The results showed that lincRNA-p21 was upregulated in stage III tumors ( p = 0.007) and in tumors with the worst response regarding TRG ( p = 0.027) and downstaging ( p = 0.016). ROC curve analysis showed that lincRNA-p21 expression had the capacity to distinguish a complete response from others (AUC:0.696; p = 0.014). LincRNA-p21 was shown as an independent marker of preoperative CRT response ( p = 0.047) and for time to relapse (TTR) ( p = 0.048). In conclusion, lincRNA-p21 is a marker of advanced disease, worse response to neoadjuvant CRT, and shorter TTR in locally advanced RC patients. The study of lincRNA-p21 may be of value in the individualization of pre-operative CRT in RC.
- Published
- 2021
- Full Text
- View/download PDF
44. A mathematical model for decision-making in the classification of para-footballers with different severity of coordination impairments.
- Author
-
Pastor D, Campayo-Piernas M, Pastor JT, and Reina R
- Subjects
- Adolescent, Adult, Athletic Performance, Persons with Disabilities, Exercise Test, Humans, Models, Theoretical, Young Adult, Ataxia diagnosis, Athletes classification, Decision Making, Soccer, Sports for Persons with Disabilities
- Abstract
Classification is a defining feature of Para-sport, and sports-specific classification systems determined through multidisciplinary scientific research are required, i.e., evidence-based and focused on the relationship between the impairment and the key performance determinants. Data envelopment analysis (DEA) was applied as a classification tool using a directional distance function (DDF) model. The aim of the study was to test the DEA as a possible classification tool in cerebral palsy football. We analyse the performance of 56 international para-footballers with hypertonia, ataxia or athetosis, who completed a 20-test battery with DEA models. Five of the tests are included in the model (change of direction: Illinois agility test; jumping: standing broad jump, four bounds for distance, and triple hop with the non-dominant leg; 10-m sprint/acceleration; and ball dribbling, both in a straight line and following a trajectory), showing that players with less impairment exhibit the highest efficiency. This outcome suggests that DEA models might be feasible for detecting and discriminating the performance and magnitude of impairment in cerebral palsy football, with an objective ranking of the athletes in relation to different physical performance tests. This study also provides reference scores for decision-making during classification and guidance for further research in team Paralympic sports.
- Published
- 2019
- Full Text
- View/download PDF
45. Correction to: SEOM clinical guideline for treatment of kidney cancer (2017).
- Author
-
Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, and Suárez C
- Abstract
The conflict of interest declaration was published incorrectly in the original version.
- Published
- 2019
- Full Text
- View/download PDF
46. How much trunk control is affected in adults with moderate-to-severe cerebral palsy?
- Author
-
Barbado D, Reina R, Roldan A, McCulloch K, Campayo-Piernas M, and Vera-Garcia FJ
- Subjects
- Adult, Female, Humans, Male, Reproducibility of Results, Cerebral Palsy physiopathology, Postural Balance, Torso physiopathology
- Abstract
Trunk control (TC) impairment is a typical feature in individuals with cerebral palsy (CP), but there are lack of methods that allow to quantify the extent to which static and dynamic TC is impaired in adults with moderate-to-severe CP. Thus, the aims of this study were to analyze the reliability of a posturography protocol to assess TC in adults with CP, and quantify their degree of TC impairment compared to a control sample of adults without CP. Forty-seven adults with moderate-to-severe CP and nineteen control participants were assessed via a protocol of static and dynamic seated trunk tasks, performed on a stable and an unstable surface placed on a force-plate. The mean radial error was the primary variable measured. A large percentage of CP participants successfully completed the static and dynamic conditions on the stable surface (static: 93.6%; dynamic: 91.5-72.3%); however, this percentage decreased considerably on the unstable surface (51.1-34.0%). The posturography protocol displayed good reliability in adults with CP (0.89 ≤ ICC ≤ 0.95; 15.2% ≤ SEM ≤ 20.7%). Adults with CP displayed significantly decreased TC in 4/5 tasks on the stable seat, particularly in dynamic conditions (1.71 ≤ d
g ≤ 1.91). Our results confirmed that TC is significantly affected in CP adults compared with controls without CP of similar age, but they present more difficulties to perform dynamic tasks. Thus, it would be recommend including dynamic in addition to static conditions to obtain a comprehensive assessment of TC impairment in adults with moderate-to-severe CP. Additional, these results encourage practitioners to design dynamic activities that challenge trunk control for rehabilitations/training programs., (Copyright © 2018 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
47. Malignant Pleural Mesothelioma: The Last 8 Years of Experience in Our Area.
- Author
-
Benítez JC, Campayo M, Call S, and Bastús R
- Subjects
- Aged, Female, Humans, Male, Mesothelioma, Malignant, Retrospective Studies, Spain, Survival Rate, Time Factors, Lung Neoplasms diagnosis, Lung Neoplasms mortality, Lung Neoplasms therapy, Mesothelioma diagnosis, Mesothelioma mortality, Mesothelioma therapy, Pleural Neoplasms diagnosis, Pleural Neoplasms mortality, Pleural Neoplasms therapy
- Published
- 2018
- Full Text
- View/download PDF
48. miR-21, miR-99b and miR-375 combination as predictive response signature for preoperative chemoradiotherapy in rectal cancer.
- Author
-
Campayo M, Navarro A, Benítez JC, Santasusagna S, Ferrer C, Monzó M, and Cirera L
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma pathology, Adenocarcinoma therapy, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Chemoradiotherapy, Cohort Studies, Endoscopy, Gastrointestinal, Female, Gene Expression Regulation, Neoplastic, Humans, Male, Middle Aged, Neoplasm Grading, Preoperative Care, Prognosis, ROC Curve, Rectal Neoplasms mortality, Rectal Neoplasms pathology, Rectal Neoplasms therapy, Survival Analysis, Adenocarcinoma metabolism, MicroRNAs metabolism, Rectal Neoplasms metabolism
- Abstract
Introduction: Preoperative chemoradiotherapy (CRT) is a standard treatment for locally advanced rectal cancer patients. Despite the benefits of CRT, its use in non-responder patients can be associated with increased toxicities and surgical resection delay. The identification of CRT response biomarkers, such as microRNAs, could improve the management of these patients. We have studied the microRNA expression in pretreatment endoscopy biopsies from rectal cancer patients treated with CRT to identify potential microRNAs able to predict CRT response and clinical outcome of these patients., Material and Methods: RNA from pretreatment endoscopy biopsies from 96 rectal cancer patients treated with preoperative CRT were studied. Pathological response was graded according to the tumor regression grade (TRG) Dworak classification. In the screening phase, 377 miRNAs were studied in 12 patients with extreme responses (TRG0-1 vs TRG4). The potential role as predictive biomarkers for CRT response, disease-free survival (DFS) and overall survival (OS) of the miRNAs identified in the screening phase were validated in the whole cohort., Results: In the screening phase, an 8-miRNAs CRT-response signature was identified: let-7b, let-7e, miR-21, miR-99b, miR-183, miR-328, miR-375 and miR-483-5p. In the validation phase, miR-21, miR-99b and miR-375 emerged as CRT response-related miRNAs while miR-328 and let-7e emerged as prognostic markers for DFS and OS. Interestingly, ROC curve analysis showed that the combination of miR-21, miR-99b and miR-375 had the best capacity to distinguish patients with maximum response (TRG4) from others., Conclusions: miR-21, miR-99b and miR-375 could add valuable information for individualizing treatment in locally advanced rectal cancer patients., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF
49. Prognostic and Predictive Factors for Renal Cell Carcinoma.
- Author
-
Suárez C, Campayo M, Bastús R, Castillo S, Etxanitz O, Guix M, Sala N, and Gallardo E
- Subjects
- Carcinoma, Renal Cell pathology, Humans, Kidney Neoplasms pathology, Prognosis, Carcinoma, Renal Cell therapy, Kidney Neoplasms therapy
- Abstract
Metastatic renal cell carcinoma (mRCC) is an incurable malignancy, characterized by its resistance to traditional chemotherapy, radiation, and hormonal therapy. Treatment perspectives and prognosis of patients with mRCC have been significantly improved by advances in the understanding of its molecular pathogenesis, which have led to the development of targeted therapeutics. Different molecular factors derived from the tumor or the host detected in both tissue or serum could be predictive of therapeutic benefit. Some of them suggest a rational selection of patients to be treated with certain therapies, though none have been validated for routine use. This article provides an overview of both clinical and molecular factors associated with predictive or prognostic value in mRCC and emphasizes that both should be considered in parallel to provide the most appropriate, individualized treatment and achieve the best outcomes in clinical practice.
- Published
- 2018
- Full Text
- View/download PDF
50. Leptomeningeal Carcinomatosis in a Patient With Clinical Stage III Lung Adenocarcinoma and Sudden Neurological Impairment.
- Author
-
Benítez JC, Bastús R, Luizaga L, Cirera L, and Campayo M
- Subjects
- Aged, Fatal Outcome, Humans, Incidental Findings, Male, Neoplasm Staging, Adenocarcinoma of Lung secondary, Consciousness Disorders etiology, Gait Disorders, Neurologic etiology, Headache etiology, Lung Neoplasms pathology, Meningeal Carcinomatosis etiology
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.